NCT02491892View on ClinicalTrials.gov

A Study of Pertuzumab in Participants With Metastatic Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

February 28, 2003

Primary Completion Date

April 30, 2005

Study Completion Date

April 30, 2005

Conditions
Breast Cancer
Interventions
DRUG

Pertuzumab

Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.

Trial Locations (18)

2050

Camperdown

3065

Fitzroy

3220

Geelong

5000

Namur

20133

Milan

20246

Hamburg

33520

Tampere

43100

Parma

44625

Herne

46009

Valencia

81675

München

00029

Helsinki

1081 HV

Amsterdam

08035

Barcelona

08907

Barcelona

EH4 2XU

Edinburgh

SE1 9RT

London

M20 4BX

Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02491892 - A Study of Pertuzumab in Participants With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter